Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2
Open Access
- 15 January 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (2), 819
- https://doi.org/10.3390/ijms22020819
Abstract
IKAROS, encoded by the IKZF1 gene, is a DNA-binding protein that functions as a tumor suppressor in T cell acute lymphoblastic leukemia (T-ALL). Recent studies have identified IKAROS’s novel function in the epigenetic regulation of gene expression in T-ALL and uncovered many genes that are likely to be directly regulated by IKAROS. Here, we report the transcriptional regulation of two genes, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (PIK3CD) and phosphoinositide kinase, FYVE-type zinc finger containing (PIKFYVE), by IKAROS in T-ALL. PIK3CD encodes the protein p110δ subunit of phosphoinositide 3-kinase (PI3K). The PI3K/AKT pathway is frequently dysregulated in cancers, including T-ALL. IKAROS binds to the promoter regions of PIK3CD and PIKFYVE and reduces their transcription in primary T-ALL. Functional analysis demonstrates that IKAROS functions as a transcriptional repressor of both PIK3CD and PIKFYVE. Protein kinase CK2 (CK2) is a pro-oncogenic kinase that is overexpressed in T-ALL. CK2 phosphorylates IKAROS, impairs IKAROS’s DNA-binding ability, and functions as a repressor of PIK3CD and PIKFYVE. CK2 inhibition results in increased IKAROS binding to the promoters of PIK3CD and PIKFYVE and the transcriptional repression of both these genes. Overall, the presented data demonstrate for the first time that in T-ALL, CK2 hyperactivity contributes to PI3K signaling pathway upregulation, at least in part, through impaired IKAROS transcriptional regulation of PIK3CD and PIKFYVE. Targeting CK2 restores IKAROS’s regulatory effects on the PI3K oncogenic signaling pathway.Funding Information
- National Center for Advancing Translational Sciences (KL2 TR002015)
- St. Baldrick's Foundation (NA)
- Hyundai Hope On Wheels (NA)
- Penn State College of Medicine (NA)
- Rally Foundation (NA)
This publication has 45 references indexed in Scilit:
- Targeting PI3K Signaling in Acute Lymphoblastic LeukemiaInternational Journal of Molecular Sciences, 2019
- CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cellsHaematologica, 2016
- Casein kinase II (CK2) as a therapeutic target for hematological malignanciesCurrent Pharmaceutical Design, 2016
- Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemiaLeukemia, 2015
- Ikaros, CK2 kinase, and the road to leukemiaMolecular and Cellular Biochemistry, 2011
- Role of Ikaros in T-cell acute lymphoblastic leukemiaWorld Journal of Biological Chemistry, 2011
- Tumor suppression in T cell leukemia—The role of IkarosLeukemia Research, 2010
- Ikaros and acute leukemia.Leukemia & Lymphoma, 2008
- Protein kinase CK2: structure, regulation and role in cellular decisions of life and deathBiochemical Journal, 2003
- Ikaros Chromatin Remodeling Complexes in the Control of Differentiation of the Hemo-lymphoid SystemCold Spring Harbor Symposia on Quantitative Biology, 1999